Kathleen Decker

Dr. Kathleen Decker

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
KDKathleen Decker
Kathleen Decker
PLPascal Lambert
Pascal Lambert
ZNZoann Nugent
Zoann Nugent
NBNatalie Biswanger
Natalie Biswanger
JSJewel Samadder
Jewel Samadder
HSHarminder Singh
Harminder Singh
Colorectal cancer (CRC) is the second most common cancer in North America, accounting for 13% of all cancer diagnoses in Canada.1 Although the incidence of CRC has decreased during the last 20 years, one-half of individuals with CRC receive the diagnosis when the cancer is in a late stage.1,2 In addition, 15% to 30% of patients with a CRC diagnosis present as an emergency.3-5 Emergencies include intestinal obstructions, perforations, or emergency admissions to the hospital (OPE) prior to diagnosis.6 Short-term7,8 and long-term9 survival for individuals with a diagnosis of CRC after an OPE is worse compared with nonemergency diagnoses even when adjusted for age and comorbidity.10 Moreover, the health care burden of emergency CRC presentations is substantial, as these patients spend greater than 50% more days in the hospital than those with nonemergency diagnoses and overall treatment costs are higher.11 Therefore, the rate of OPE among individuals who present with a new CRC diagnosis is a useful quality indicator because it represents a missed opportunity to diagnose CRC early.12-16

5 September 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
KDKathleen Decker
Kathleen Decker
AFAllison Feely
Allison Feely
OBOliver Bucher
Oliver Bucher
PCPiotr Czaykowski
Piotr Czaykowski
PHPamela Hebbard
Pamela Hebbard
PLPascal Lambert
Pascal Lambert
The COVID-19 pandemic led to the reorganization of health services to provide care for patients with COVID-19. This reorganization included greater use of virtual visits, temporary suspension of or reduction in cancer screening and diagnostic services, triaging patients with cancer for treatment based on acuity, and the redeployment of cancer care staff. Measures to address COVID-19 also varied throughout Canada and over time as COVID-19 caseloads changed.1

1 October 2021 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
MSMorgan Stirling
Morgan Stirling
AAAlexandrea Anderson
Alexandrea Anderson
HOHelene Ouellette-Kuntz
Helene Ouellette-Kuntz
JHJulie Hallet
Julie Hallet
SSShahin Shooshtari
Shahin Shooshtari
AMAlyson Mahar
Alyson Mahar

19 January 2022 in Preventive Medicine
Verified
Journal Article
Open access
KDKathleen Decker
Kathleen Decker
AFAllison Feely
Allison Feely
OBOliver Bucher
Oliver Bucher
HSHarminder Singh
Harminder Singh
DTDonna Turner
Donna Turner
PLPascal Lambert
Pascal Lambert
We evaluated the impact of COVID-19 on cancer screening in Manitoba, Canada using an interrupted time series (ITS) design and data from Manitoba's population-based, organized cancer screening programs from April 2020 to August 2021. In June 2020 (breast screening was suspended during April and May 2020), there was a 54% decrease between the predicted (i.e., observed data produced from regression models) and expected (i.e., counterfactual values produced for the COVID-19 period by assuming COVID-19 did not occur) number of screening mammograms (ratio = 0.46, 95% Confidence Interval (CI) 0.28–0.64). By December 2020, there was no significant difference between predicted and expected number of screening mammograms (ratio = 0.95, 95% CI 0.80–1.10). In April 2020, there was an 83% decrease in the number of Pap tests (ratio = 0.17, 95% CI 0.04–0.30). By January 2021, there was no significant difference between predicted and expected number of Pap tests (ratio = 0.93, 95% CI 0.81–1.06). In April 2020, there was an 81% decrease in the number of screening program fecal occult blood tests (FOBTs) (ratio = 0.19, 95% CI 0.0–0.44). By September 2020, there was no significant difference between predicted and expected number of FOBTs (ratio = 0.95, 95% CI 0.65–1.24). The estimated cumulative deficit (i.e., backlog) from April 2020 to August 2021 was 17,370 screening mammograms, 22,086 Pap tests, and 5253 screening program FOBTs. Overall, screening programs adapted quickly to the COVID-19 pandemic. Additional strategies may be needed to address remaining backlogs.

1 June 2019 in Current Oncology
Verified
Journal Article
Open access
FJF. Jalili
F. Jalili
COC. O’cOnaill
C. O’cOnaill
KTK. Templeton
K. Templeton
RLR. Lotocki
R. Lotocki
GFG. Fischer
G. Fischer
KDKathleen Decker
Kathleen Decker
Background: CervixCheck, Manitoba’s cervical cancer screening program, conducted a pilot study to assess whether screening participation could be improved in unscreened women by offering a mailed self-sampling kit for human papillomavirus (HPV) testing instead of a Pap test. Methods: In a prospective cohort study design, a sample of unscreened women (n = 1052) who had been sent an invitation letter from CervixCheck in the past but who did not respond were randomized to either an intervention group or a control group. The intervention group received a mailed HPV self-sampling kit; the control group received no additional communication. Returned HPV self-sampling swabs were analyzed by a provincial laboratory. After 6 months, screening participation in the two study groups was compared using a logistic regression model adjusted for age and area of residence (urban or rural). Secondary outcomes included HPV positivity, specimen inadequacy, compliance with follow-up, and time to colposcopy. Results: Screening participation was significantly higher in the intervention group than in the control group (n = 51, 9.6%, vs. n = 13, 2.5%; odds ratio: 4.7; 95% confidence interval: 2.56 to 8.77). Geographic area of residence (urban or rural) and age were not statistically significant. Conclusions: The study demonstrated that HPV self-sampling kits can enhance screening participation in unscreened non-responder women in the setting of an organized screening program. Next steps should include additional research to determine the best implementation strategy for HPV self-sampling in Manitoba.

1 August 2016 in Current Oncology
Verified
Journal Article
Open access
KDKathleen Decker
Kathleen Decker
EKE.V. Kliewer
E.V. Kliewer
ADA.A. Demers
A.A. Demers
KFK. Fradette
K. Fradette
NBN. Biswanger
N. Biswanger
DTD. Turner
D. Turner
Background: In the present study, we examined breast (BCa) and colorectal cancer (CRC) incidence and mortality and stage at diagnosis for First Nations (FN) individuals and all other Manitobans (AOMS). Methods: Several population-based databases were linked to determine ethnicity and to calculate age-standardized incidence and mortality rates. Logistic regression was used to compare BCa and CRC stage at diagnosis. Results: From 1984–1988 to 2004–2008, the incidence of BCa increased for FN and aom women. Breast cancer mortality increased for fn women and decreased for AOM women. First Nations women were significantly more likely than aom women to be diagnosed at stages III–IV than at stage I [odds ratio (OR) for women ≤50 years of age: 3.11; 95% confidence limits (CL): 1.20, 8.06; OR for women 50–69 years of age: 1.72; 95% CL: 1.03, 2.88). The incidence and mortality of CRC increased for FN individuals, but decreased for AOMS. First Nations status was not significantly associated with CRC stage at diagnosis (OR for stages I–II compared with stages III–IV: 0.98; 95% CL: 0.68, 1.41; OR for stages I–III compared with stage IV: 0.91; 95% CL: 0.59, 1.40). Conclusions: Our results underscore the need for improved cancer screening participation and targeted initiatives that emphasis collaboration with fn communities to reduce barriers to screening and to promote healthy lifestyles.